Werlinich Asset Management, LLC Crispr Therapeutics Ag Transaction History

Werlinich Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Nov 13, 2023	SELL	$70.09 - $111.29 $454,533 - $721,715	-6,485 Closed	0 $0
Q3 2021 Nov 13, 2023	SELL	$110.2 - $156.64 $20,387 - $28,978	-185 Reduced 2.77%	6,485 $726 Million
Q2 2021 Nov 13, 2023	BUY	$100.84 - $161.89 $29,243 - $46,948	290 Added 4.55%	6,670 $1.08 Billion
Q1 2021 Nov 13, 2023	BUY	$110.72 - $210.04 $706,393 - $1.34 Million	6,380 New	6,380 $777 Million

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.2B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Werlinich Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Werlinich Asset Management, LLC with notifications on news.